Sporadic Medullary Thyroid Cancer

Part of the Cancer Treatment and Research book series (CTAR, volume 153)


Medullary thyroid cancer (MTC), is a tumor of the parafollicular / c-cells of the thyroid gland. These cells are derived from the embryonic neural crests and make up 1% of the thyroid cells. C-cells can be found anywhere in the gland but are concentrated in the upper poles of the thyroid lobes. Among other substances, these cells produce calcitonin which contributes to the regulation of serum calcium. This tumor, first described in 1959, is characterized by early spread to regional lymph nodes, and long-term survival even with disseminated disease [1]. Common sites of distant metastases include lung, liver, brain, bone, and soft tissue [2].


Total Thyroidectomy Medullary Thyroid Cancer Calcitonin Level Nodular Thyroid Disease Biochemical Cure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hazard JB, Hawk WA, Crile G Jr (1959) Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19(1):152–161CrossRefPubMedGoogle Scholar
  2. 2.
    Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31(5):946–956CrossRefPubMedGoogle Scholar
  3. 3.
    Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L et al (1994) Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 367(6461):378–380CrossRefPubMedGoogle Scholar
  4. 4.
    Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA (1989) Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111(10):802–806PubMedGoogle Scholar
  5. 5.
    Howe JR, Norton JA, Wells SA Jr (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114(6):1070–1077PubMedGoogle Scholar
  6. 6.
    O’Riordain DS, O’Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA (1995) Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118(6):936–942CrossRefPubMedGoogle Scholar
  7. 7.
    Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367(6461):375–376CrossRefPubMedGoogle Scholar
  8. 8.
    Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428):458–460CrossRefPubMedGoogle Scholar
  9. 9.
    Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E et al (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6(1):70–74CrossRefPubMedGoogle Scholar
  10. 10.
    Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Haas OA, Vierhapper H et al (2001) Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 25(10):1245–1251CrossRefPubMedGoogle Scholar
  11. 11.
    Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517–1525CrossRefPubMedGoogle Scholar
  12. 12.
    Fialkowski EA, Moley JF (2006) Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94(8):737–747CrossRefPubMedGoogle Scholar
  13. 13.
    Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C et al (2006) Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest 29(5):427–437PubMedGoogle Scholar
  14. 14.
    Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89(1):163–168CrossRefPubMedGoogle Scholar
  15. 15.
    Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP et al (1997) Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 82(2):338–341CrossRefPubMedGoogle Scholar
  16. 16.
    de Groot JW, Kema IP, Breukelman H, van der Veer E, Wiggers T, Plukker JT et al (2006) Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid 16(11):1163–1170CrossRefPubMedGoogle Scholar
  17. 17.
    Laure GA, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158(2):239–246CrossRefGoogle Scholar
  18. 18.
    Machens A, Ukkat J, Hauptmann S, Dralle H (2007) Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 142(3):289–293CrossRefPubMedGoogle Scholar
  19. 19.
    Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E et al (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725–4729CrossRefPubMedGoogle Scholar
  20. 20.
    Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  21. 21.
    Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48(3):265–273CrossRefGoogle Scholar
  22. 22.
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139–1148CrossRefPubMedGoogle Scholar
  23. 23.
    Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J (2005) Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200(6):890–896CrossRefPubMedGoogle Scholar
  24. 24.
    Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Kuma S et al (2000) Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. World J Surg 24(11):1367–1372CrossRefPubMedGoogle Scholar
  25. 25.
    Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y et al (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26(8):1023–1028CrossRefPubMedGoogle Scholar
  26. 26.
    Machens A, Hauptmann S, Dralle H (2007) Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 31(10):1960–1965CrossRefPubMedGoogle Scholar
  27. 27.
    de Groot JW, Links TP, Sluiter WJ, Wolffenbuttel BH, Wiggers T, Plukker JT (2007) Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery. Head Neck 29(9):857–863CrossRefPubMedGoogle Scholar
  28. 28.
    Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229(6):880–887CrossRefPubMedGoogle Scholar
  29. 29.
    Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J et al (2000) Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89(1):202–217CrossRefPubMedGoogle Scholar
  30. 30.
    Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E (1992) Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 40(3–4):264–267PubMedGoogle Scholar
  31. 31.
    Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H et al (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24(2):112–121CrossRefPubMedGoogle Scholar
  32. 32.
    Ellenhorn JD, Shah JP, Brennan MF (1993) Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 114(6):1078–1081PubMedGoogle Scholar
  33. 33.
    Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herfarth C (1993) Medullary carcinoma of the thyroid – therapeutic strategy derived from fifteen years of experience. Surgery 114(3):491–496PubMedGoogle Scholar
  34. 34.
    Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R et al (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130(6):1044–1049CrossRefPubMedGoogle Scholar
  35. 35.
    Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890–899CrossRefPubMedGoogle Scholar
  36. 36.
    Greenblatt DY, Elson D, Mack E, Chen H (2007) Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 30(2):108–112CrossRefPubMedGoogle Scholar
  37. 37.
    Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV et al (1999) Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230(5):697–707CrossRefPubMedGoogle Scholar
  38. 38.
    Dralle H (2002) Lymph node dissection and medullary thyroid carcinoma. Br J Surg 89(9):1073–1075CrossRefPubMedGoogle Scholar
  39. 39.
    Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S et al (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88(5):2070–2075CrossRefPubMedGoogle Scholar
  40. 40.
    Kebebew E, Clark OH (2000) Medullary thyroid cancer. Curr Treat Options Oncol 1(4):359–367CrossRefPubMedGoogle Scholar
  41. 41.
    Hamy A, Pessaux P, Mirallie E, Mucci-Hennekinne S, Gibelin H, Mor-Martinez C et al (2005) Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol 31(7):774–777CrossRefPubMedGoogle Scholar
  42. 42.
    Dotzenrath C, Goretzki PE, Cupisti K, Simon D, Witte J, Yang Q et al (2001) Is there any consensus in diagnostic and operative strategy with respect to medullary thyroid cancer? A questionnaire answered by 73 endocrine surgical units. Langenbecks Arch Surg 386(1):47–52CrossRefPubMedGoogle Scholar
  43. 43.
    Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP et al (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88(10):1537–1542CrossRefPubMedGoogle Scholar
  44. 44.
    Quayle FJ, Moley JF (2005) Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 89(3):122–129CrossRefPubMedGoogle Scholar
  45. 45.
    Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99(1):60–66PubMedGoogle Scholar
  46. 46.
    Kebebew E, Kikuchi S, Duh QY, Clark OH (2000) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135(8):895–901CrossRefPubMedGoogle Scholar
  47. 47.
    Moley JF, Wells SA, Dilley WG, Tisell LE (1993) Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114(6):1090–1095PubMedGoogle Scholar
  48. 48.
    Fialkowski E, Debenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32(5):754–765CrossRefPubMedGoogle Scholar
  49. 49.
    Juweid M, Sharkey RM, Swayne LC, Goldenberg DM (1997) Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies. Surgery 122(6):1156–1165CrossRefPubMedGoogle Scholar
  50. 50.
    Moley JF, Dilley WG, DeBenedetti MK (1997) Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225(6):734–740CrossRefPubMedGoogle Scholar
  51. 51.
    Vriens B, Van Hee R (2007) Re-operation for recurrent lymph node metastasis of medullary thyroid cancer – is it useful? Acta Chir Belg 107(3):331–335PubMedGoogle Scholar
  52. 52.
    Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L et al (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185–4190CrossRefPubMedGoogle Scholar
  53. 53.
    de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11(8):786–794CrossRefPubMedGoogle Scholar
  54. 54.
    Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C et al (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92(12):4590–4597CrossRefPubMedGoogle Scholar
  55. 55.
    Tung WS, Vesely TM, Moley JF (1995) Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118(6):1024–1029CrossRefPubMedGoogle Scholar
  56. 56.
    van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212(4):395–400CrossRefPubMedGoogle Scholar
  57. 57.
    Fernandez Vila JM, Peix JL, Mandry AC, Mezzadri NA, Lifante JC (2007) Biochemical results of reoperations for medullary thyroid carcinoma. Laryngoscope 117(5):886–889CrossRefPubMedGoogle Scholar
  58. 58.
    Faik EM, Gursoy A, Erdogan G, Kamel N (2006) Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 27(4):359–362CrossRefGoogle Scholar
  59. 59.
    Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M (2000) Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 83(6):715–718CrossRefPubMedGoogle Scholar
  60. 60.
    Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5(8):763–765PubMedGoogle Scholar
  61. 61.
    Scherubl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116(1):21–23CrossRefPubMedGoogle Scholar
  62. 62.
    Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71(2):363–365PubMedGoogle Scholar
  63. 63.
    de Groot JW, Plaza MI, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT et al (2006) Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 139(6):806–814CrossRefPubMedGoogle Scholar
  64. 64.
    de Groot JW, Zonnenberg BA, Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ et al (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92(9):3466–3469CrossRefPubMedGoogle Scholar
  65. 65.
    Ezzat S, Huang P, Dackiw A, Asa SL (2005) Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11(3):1336–1341PubMedGoogle Scholar
  66. 66.
    Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F (2007) Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157(2):215–220CrossRefPubMedGoogle Scholar
  67. 67.
    Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J et al (2008) Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7(5):1001–1006CrossRefPubMedGoogle Scholar
  68. 68.
    Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW et al (2006) Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91(1):79–84CrossRefPubMedGoogle Scholar
  69. 69.
    Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B et al (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24(11):1705–1711CrossRefPubMedGoogle Scholar
  70. 70.
    Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC et al (2000) Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 41(1):93–103PubMedGoogle Scholar
  71. 71.
    Kraeber-Bodere F, Sai-Maurel C, Campion L, Faivre-Chauvet A, Mirallie E, Cherel M et al (2002) Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 1(4):267–274PubMedGoogle Scholar
  72. 72.
    Stein R, Goldenberg DM (2004) A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 3(12):1559–1564PubMedGoogle Scholar
  73. 73.
    Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ (2005) Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26(11):969–976CrossRefPubMedGoogle Scholar
  74. 74.
    Gao ZR, An R, Zhang YX, Biersack HJ (2006) Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma. Zhonghua Zhong Liu Za Zhi 28(8):621–624PubMedGoogle Scholar
  75. 75.
    Pasieka JL, McEwan AJ, Rorstad O (2004) The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136(6):1218–1226CrossRefPubMedGoogle Scholar
  76. 76.
    Samaan NA, Schultz PN, Hickey RC (1989) Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res Suppl 21:21–25PubMedGoogle Scholar
  77. 77.
    Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305–310CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of SurgeryFoothills Medical CentreCalgaryCanada

Personalised recommendations